TLDR
- Barclays analyst moved Alvotech from Underweight to Overweight, increasing the price target from $4 to $8
- FDA completed its inspection of the Iceland manufacturing site with a positive “Voluntary Action Indicated” outcome in July
- FDA decision deadline for three biosimilar applications (AVT05, AVT06, AVT03) is set for December 4, 2026
- Company maintained its fiscal 2026 revenue projection between $650 million and $700 million
- Shares rose approximately 8% on Wednesday, representing the largest daily increase since December
Alvotech shares surged approximately 8% during Wednesday’s trading session after Glen Santangelo, a Barclays analyst, upgraded the stock from Underweight to Overweight while simultaneously doubling his price target from $4 to $8. Trading at around $5.42, the stock remains significantly below its 52-week peak of $9.25.
This surge represents one of the most significant single-session advances for the stock, according to Dow Jones Market Data, with the gain representing the strongest performance since last December.
The analyst’s upgrade comes on the heels of an important regulatory milestone. In July, the FDA concluded its inspection of Alvotech’s Reykjavik, Iceland production facility, assigning it a Voluntary Action Indicated classificationāthe agency’s most positive inspection result.
The Icelandic manufacturing site had been a point of investor anxiety. Earlier FDA inspections had identified shortcomings in manufacturing protocols and facility compliance, creating obstacles for product authorizations. Importantly, the issues were facility-related rather than product-specific.
Following the resolution of facility concerns, Alvotech resubmitted biologics license applications in June covering three biosimilar candidates. The FDA has established December 4, 2026 as the target action date for all three submissions.
Three Drugs in the Pipeline
The trio of biosimilar candidates targets therapeutic areas including chronic inflammation, eye diseases, and skeletal health.
AVT05 represents a biosimilar alternative to Johnson and Johnson’s Simponi, prescribed for joint pain reduction. AVT06 is Alvotech’s biosimilar version of Eylea, a collaboration between Regeneron and Bayer for treating retinal conditions and preserving vision. AVT03 aims to replicate Amgen’s Prolia and Xgeva, both used for bone protection.
Additionally, the FDA has accepted a biologics license application for AVT16, a biosimilar to Entyvio, with an anticipated decision in early 2027.
Santangelo observed that the facility returned to full production capacity during the second quarter of 2026. Company leadership confirmed its fiscal 2026 revenue forecast ranging from $650 million to $700 million.
Expansion Plans Beyond Iceland
Beyond its Icelandic operations, Alvotech is pursuing additional manufacturing capacity. The company has established a strategic partnership with Fujifilm Biotechnologies in the United States, with enhanced production capabilities anticipated to become operational in 2027.
Santangelo characterized the stock as an appealing investment opportunity, pointing to regulatory advancements and the defined timeline for potential approvals before the end of the year.
The overall market showed modest gains on Wednesday, with the S&P 500 advancing 0.2% and the Nasdaq climbing 0.4%, though Alvotech’s performance significantly exceeded broader market movements.
Currently trading substantially below its 52-week high of $9.25, the stock awaits three critical FDA determinations scheduled for December 4, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
